CD4 and neoplasm: We also unveiled that CD70-targeted cusatuzumab treatment destabilized Tregs in a manner dependent on the CD70 expression level on tumor cells, the CD27 expression level on CD4+ T cells, and the CD4+/CD8+ ratio in the TME.